GU Cancers 2023 | KEYNOTE-057 Cohort B: pembrolizumab for BCG-unresponsive, high-risk NMIBC

Andrea Necchi, MD, Vita-Salute San Raffaele University and IRCCS San Raffaele Hospital and Scientific Institute, Milan, Italy, provides an overview of the Phase II KEYNOTE-057 trial (NCT02625961) and discusses results from Cohort B. The aim of the trial was to evaluate pembrolizumab for the treatment of high-risk non-muscle-invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guérin (BCG). The primary endpoint was a 12-month disease-free survival, which was met by 43% of patients in Cohort B. No new safety signals were identified and patient quality of life was reported to be good. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.